Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 247,200 shares of common stock to eight employees as an inducement for them entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral table ...